SeaStar medical shares are trading higher on continued upward momentum after the FDA granted the company's Selective Cytopheretic Device Breakthrough Device Designation for hepatorenal syndrome.
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical's shares are trading higher following the FDA's Breakthrough Device Designation for the company's Selective Cytopheretic Device for hepatorenal syndrome.
October 19, 2023 | 3:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical's stock is trading higher after the FDA granted Breakthrough Device Designation for its Selective Cytopheretic Device.
The FDA's Breakthrough Device Designation is a significant regulatory milestone that can accelerate the development and review process for medical devices. This news is likely to boost investor confidence in SeaStar Medical, leading to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100